Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Altimmune

Altimmune Q2 FY2025 Earnings Call Transcript

Altimmune, Inc. (NASDAQ:ALT) reported its second-quarter financial results before Tuesday’s opening bell.

2 Small-Cap Stocks Under $20 With Over 220% Upside Potential

2 Small-Cap Stocks Under $20 With Over 220% Upside Potential

Wall Street is forecasting multibagger returns from these two small-cap biotech stocks over the next year.

New weight loss drugs are on the way — and the health benefits are even more promising

New weight loss drugs are on the way — and the health benefits are even more promising

New drugs could improve liver and heart function while reducing side effects such as muscle loss and nausea common to existing medications

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review

The stock market is right at record highs amid big earnings movers and economic data that didn't spook bond markets.

Investors Business Daily

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know

Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24 hours, at $5.26 per share. A move to $25.00 would account for a 375.29% increase from the current…

Altimmune: Q1 Earnings Insights

Altimmune: Q1 Earnings Insights

Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Altimmune Earnings Perspective: Return On Capital Employed

Altimmune Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89 million.

Altimmune: Q4 Earnings Insights

Altimmune: Q4 Earnings Insights

Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Altimmune's Earnings Outlook

Altimmune's Earnings Outlook

Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate that Altimmune will report an earnings per share (EPS) of $-0.65.

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

The FDA has cleared Altimmune Inc's (NASDAQ:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Dell Technologies

Monster Beverage

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Macular Degeneration

Places

302,789 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play